by Eric Christianson | Nov 25, 2018 | Cardiovascular Medication and Disease State Clinical Pearls, Drug Interaction Case Studies and Education For Pharmacists, Medication and Disease State Clinical Pearls For Pharmacists
Apixaban (Eliquis) is a somewhat newer anticoagulant. While it is tempting to utilize the “set it and forget it” mindset with dosing, we must remember that there are a few reasons that we might have to make apixaban dose adjustments. Apixaban dose...
by Eric Christianson | Nov 14, 2018 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Today I’m going to discuss a case involving a patient concern with inappropriate production of milk (formally known as galactorrhea). Keep an eye at the end of this post for some MAJOR announcements about upcoming content releases! For now, here’s the...
by Eric Christianson | Nov 7, 2018 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Should we use cilostazol in heart failure? A 68 year old male smoker has a past medical history of peripheral vascular disease, cardiovascular disease, myocardial infarction X2, osteoarthritis, CHF and constipation. He has an extensive medication list that includes;...
by Eric Christianson | Oct 31, 2018 | Medication and Disease State Clinical Pearls For Pharmacists, Personal Stories From The Front Lines of Clinical Pharmacy, Psychiatry and Addiction Medicine Case Studies
Patient misconceptions with antidepressant therapy is very common. Antidepressant therapy can be life changing for patients, but we have to remember that their are very critical education points that we need to help coach them on. Here’s a list of a few patient...
by Eric Christianson | Oct 17, 2018 | Medication and Disease State Clinical Pearls For Pharmacists, Psychiatry and Addiction Medication and Disease State Clinical Pearls
I’ve covered many potential adverse effects and clinical quirks with the SSRI’s on this podcast, but one mystery still remains. What to do about the SSRI platelet inhibition effect? The SSRI platelet inhibition effect is a real clinical conundrum. If...
by Eric Christianson | Oct 10, 2018 | Medication and Disease State Clinical Pearls For Pharmacists, Pharmacogenomics and Pharmacokinetics Medication and Disease State Clinical Pearls
What the heck is HLA B*5701? Let’s start with the HLA. HLA stands for human leukocyte antigen. The rest of the name is simply indicating that it is subtype of HLA. There are many different subtypes of HLA as mentioned with each specific medication below. You...
